The effect of rivaroxaban and enoxaparin on the prophylaxis of venous thromboembolism

A clinical trial to compare the effect of rivaroxaban with enoxaparin on the prophylaxis of venous thromboembolism in patients undergoing knee or hip arthroplasty surgery.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20161121031003N4

Enrollment

150

Registered

2019-12-22

Start date

2020-03-18

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee or hip arthroplasty surgery. Complications of internal orthopaedic prosthetic devices, implants and grafts

Interventions

Intervention 1: The intervention group I will receive 40 mg enoxaparin (Rolexan, Ronakdaru, Iran) subcutaneously on a daily basis for 14 days, followed by the administration of 325 mg aspirin daily fo

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: More than 18 years of age Who are candidate for hip or knee arthroplasty surgery

Exclusion criteria

Exclusion criteria: Severe side effects of a drug Moderate to severe hepatic disorder Cardiovascular diseases

Design outcomes

Primary

Measure	Time frame
Deep vein thrombosis. Timepoint: 6, 12, and 24 weeks after the intervention. Method of measurement: Doppler ultrasound.	—

Secondary

Measure	Time frame
The side effects of wounds. Timepoint: 6, 12, and 24 weeks after the intervention. Method of measurement: Questionnaire.;Wound infection. Timepoint: 6, 12, and 24 weeks after the intervention. Method of measurement: Questionnaire.;Gastrointestinal complications. Timepoint: 6, 12, and 24 weeks after the intervention. Method of measurement: Questionnaire.;Skin complications. Timepoint: 6, 12, and 24 weeks after the intervention. Method of measurement: Questionnaire.;Severe bleeding. Timepoint: 6, 12, and 24 weeks after the intervention. Method of measurement: Questionnaire.	—

Measure

Time frame

The side effects of wounds. Timepoint: 6, 12, and 24 weeks after the intervention. Method of measurement: Questionnaire.;Wound infection. Timepoint: 6, 12, and 24 weeks after the intervention. Method of measurement: Questionnaire.;Gastrointestinal complications. Timepoint: 6, 12, and 24 weeks after the intervention. Method of measurement: Questionnaire.;Skin complications. Timepoint: 6, 12, and 24 weeks after the intervention. Method of measurement: Questionnaire.;Severe bleeding. Timepoint: 6, 12, and 24 weeks after the intervention. Method of measurement: Questionnaire.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMostafa Salehpour

Iran University of Medical Sciences

gharanizadeh.k@iums.ac.ir+98 21 3354 2001

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026